CLL6 (Roche): a randomised, phase II trial of fludarabine, cyclophosphamide and rituximab (FCR) with or without mitoxantrone in previously untreated chronic lymphocytic leukaemia.

Trial Profile

CLL6 (Roche): a randomised, phase II trial of fludarabine, cyclophosphamide and rituximab (FCR) with or without mitoxantrone in previously untreated chronic lymphocytic leukaemia.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Oct 2017

At a glance

  • Drugs Mitoxantrone (Primary) ; Rituximab (Primary) ; Cyclophosphamide; Cyclophosphamide; Fludarabine; Fludarabine
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Acronyms ADMIRE; CLL6
  • Most Recent Events

    • 01 Oct 2017 Primary endpoint of proportion of patients achieving a complete response at 3 months has not been met, according to results published in the Leukemia.
    • 01 Oct 2017 Results published in the Leukemia
    • 02 Jul 2012 Status changed from active, no longer recruiting to completed as reported by ISRCTN.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top